Zymeworks is due $55.0 million after U.S. clearance, and Roche will cover most later testing and sales costs. Zymeworks gives Roche exclusive worldwide rights, and much of the possible future money depends on trial progress and sales.
The agreement gives Zymeworks cash and shifts most later testing and sales costs to Roche. The trade-off is that Zymeworks grants Roche sole rights in this treatment area for a set period. Much of the additional money depends on trial progress and sales.
Follow Zymeworks Inc. (ZYME) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ZYME